Company intelligence / Profile preview

Biotron Pharmaceuticals

Sydney, New South Wales, Australiaau.linkedin.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Biotron’s lead compound BIT225 is in Phase 2 development for HIV‑1 and SARS‑CoV‑2. It has shown safety and efficacy in boosting immune responses and reducing viral markers in HIV‑1 patients. Preclinical data support activity against COVID‑19. The pipeline includes early-stage programs targeting other significant viral diseases such as hepatitis B, dengue, Zika, influenza, and Ebola

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Biotron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotron Pharmaceuticals.

Explore the full profile